Screener
Sarepta Therapeutics, Inc. SRPT Contract Liabilities
Contract Liabilities at other companies
Other financials
Where this comes from
Reported directly by Sarepta Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.
The source filing: Sarepta Therapeutics, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:01 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-335003
| Line item | As of June 30, 2026 | As of December 31, 2025 |
|---|---|---|
| Total current liabilities | 502,908 | 1,095,290 |
| Long-term debt | 847,623 | 828,974 |
| Lease liabilities, net of current portion | 198,226 | 199,378 |
| Deferred revenue, net of current portion | 110,132 | 83,910 |
| Other non-current liabilities | 1,825 | 1,529 |
| Total liabilities | 1,660,714 | 2,209,081 |
| Commitments and contingencies (Note 16) | ||
| Stockholders’ equity: |
Item 1. Financial Statements
FAQ
- What is Sarepta Therapeutics, Inc.'s contract liabilities?
- Sarepta Therapeutics, Inc. (SRPT) reported contract liabilities of $110.13M in Q2 2026.
- What is the long-term trend for Sarepta Therapeutics, Inc.'s contract liabilities?
- Over 5 years (2020 to 2025), Sarepta Therapeutics, Inc.'s contract liabilities has grown at a -33.9% compound annual growth rate (CAGR), from $663.49M to $83.91M.
- What does contract liabilities mean?
- Revenue collected or billed in advance of performance — deferred revenue under ASC 606 terminology, representing future revenue obligations.
Ask your AI about Sarepta Therapeutics, Inc.'s contract liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude